Corpus overview


Overview

MeSH Disease

Human Phenotype

Transmission

Seroprevalence
    displaying 1 - 10 records in total 105
    records per page




    Age TRANS-dependent regulation of SARS-CoV-2 cell entry genes and cell death programs correlates with COVID-19 disease severity

    Authors: Zintis Inde; Clarence Yapp; Gaurav N Joshi; Johan Spetz; Cameron Fraser; Brian Deskin; Elisa Ghelfi; Chhinder Sodhi; David Hackam; Lester Kobzik; Ben Croker; Douglas Brownfield; Hongpeng Jia; Kristopher A. Sarosiek; Paige D. Hall; Maud Jansen; Kumaran Shanmugarajah; Jessica S. Donington; Florian Krammer; Daved Fremont; Andrzej Joachimiak; Yoshihiro Kawaoka; Vera Tesic; Maria Lucia Madariaga; Patrick C Wilson; Martin Pettersson; Mattew R. Reese; Thomas Rogers; Michelle I Rossulek; Jean G Sathish; Claire Steppan; Martyn Ticehurst; Lawrence W. Updyke; Yuao Zhu; Jun Wang; Arnab K Chatterjee; Andrew D Mesecar; Annaliesa S. Anderson; Charlotte Allerton

    doi:10.1101/2020.09.13.276923 Date: 2020-09-13 Source: bioRxiv

    Angiotensin-converting enzyme 2 (ACE2) maintains cardiovascular and renal homeostasis MESHD but also serves as the entry receptor for the novel severe acute respiratory syndrome coronavirus (SARS-CoV-2) MESHD, the causal agent of novel coronavirus disease MESHD 2019 (COVID-19)1. COVID-19 disease severity, while highly variable, is typically lower in pediatric patients than adults TRANS (particularly the elderly TRANS), but increased rates of hospitalizations requiring intensive care are observed in infants than in older children TRANS. The reasons for these differences are unknown. To detect potential age TRANS-based correlates of disease severity, we measured ACE2 protein expression at the single cell level in human lung tissue specimens from over 100 donors from [~]4 months to 75 years of age TRANS. We found that expression of ACE2 in distal lung epithelial cells generally increases with advancing age TRANS but exhibits extreme intra- and inter-individual heterogeneity. Notably, we also detected ACE2 expression on neonatal airway epithelial cells and within the lung parenchyma. Similar patterns were found at the transcript level: ACE2 mRNA is expressed in the lung and trachea shortly after birth, downregulated during childhood, and again expressed at high levels in late adulthood in alveolar epithelial MESHD cells. Furthermore, we find that apoptosis, which is a natural host defense system against viral infection MESHD, is also dynamically regulated during lung maturation, resulting in periods of heightened apoptotic priming and dependence on pro-survival BCL-2 family proteins including MCL-1. Infection of human lung cells with SARS-CoV-2 triggers an unfolded protein stress response and upregulation of the endogenous MCL-1 inhibitor Noxa; in juveniles, MCL-1 inhibition is sufficient to trigger apoptosis in lung epithelial cells - this may limit virion production and inflammatory signaling. Overall, we identify strong and distinct correlates of COVID-19 disease severity across lifespan and advance our understanding of the regulation of ACE2 and cell death programs in the mammalian lung. Furthermore, our work provides the framework for potential translation of apoptosis modulating drugs as novel treatments for COVID-19.

    Daytime variation in SARS-CoV-2 infection MESHD and cytokine production

    Authors: Aissatou Bailo Diallo; Laetitia Gay; Benjamin Coiffard; Marc Leone; Soraya Mezouar; Jean-Louis Mège; Elisa Ghelfi; Chhinder Sodhi; David Hackam; Lester Kobzik; Ben Croker; Douglas Brownfield; Hongpeng Jia; Kristopher A. Sarosiek; Paige D. Hall; Maud Jansen; Kumaran Shanmugarajah; Jessica S. Donington; Florian Krammer; Daved Fremont; Andrzej Joachimiak; Yoshihiro Kawaoka; Vera Tesic; Maria Lucia Madariaga; Patrick C Wilson; Martin Pettersson; Mattew R. Reese; Thomas Rogers; Michelle I Rossulek; Jean G Sathish; Claire Steppan; Martyn Ticehurst; Lawrence W. Updyke; Yuao Zhu; Jun Wang; Arnab K Chatterjee; Andrew D Mesecar; Annaliesa S. Anderson; Charlotte Allerton

    doi:10.1101/2020.09.09.290718 Date: 2020-09-12 Source: bioRxiv

    S. Ray and A. Reddy recently anticipated the implication of circadian rhythm in severe acute respiratory syndrome coronavirus 2 MESHD (SARS-CoV-2), which is the causative agent of the coronavirus disease MESHD (Covid-19). In addition to its key role in the regulation of biological functions, the circadian rhythm has been suggested as a regulator of viral infections MESHD. Specifically, the time of day of infection MESHD was found critical for illness progression, as has been reported for influenza, respiratory syncytial and parainfluenza type 3 viruses. We analyzed circadian rhythm implication in SARS-CoV-2 virus infection MESHD of isolated human monocytes, key actor cells in Covid-19 disease, from healthy subjects. The circadian gene expression of Bmal1 and Clock genes was investigated with q-RTPCR. Monocytes were infected with SARS-CoV-2 virus strain and viral infection MESHD was investigated by One-Step qRT-PCR and immunofluorescence. Interleukin (IL)-6, IL-1{beta} and IL-10 levels were also measured in supernatants of infected monocytes. Using Cosinor analysis, we showed that Bmal1 and Clock transcripts exhibited circadian rhythm in monocytes with an acrophase and a bathyphase at Zeitgeber Time (ZT)6 and ZT17. After forty-eight hours, the amount of SARS-CoV-2 virus increased in the monocyte infected at ZT6 compared to ZT17. The high virus amount at ZT6 was associated with significant increased release in IL-6, IL-1{beta} and IL-10 compared to ZT17. Our results suggest that time day of SARS-CoV-2 infection affects viral infection MESHD and host immune response. They support consideration of circadian rhythm in SARS-CoV-2 disease MESHD progression and we propose circadian rhythm as a novel target for managing viral progression. ImportanceThe implication of circadian rhythm (CR) in pathogenesis of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has been recently anticipated. The time of day of infection is critical for illness progression as reported for influenza, respiratory syncytial and parainfluenza type 3 viruses. In this study, we wondered if SARS-CoV-2 infection and cytokine production by human monocytes, innate immune cells affected by Covid-19, were regulated by CR. Our results suggest that time day of SARS-CoV-2 infection affects viral infection and host immune response. They support consideration of circadian rhythm in SARS-CoV-2 disease progression and we propose circadian rhythm as a novel target for managing viral progression.

    Evaluating ten commercially-available SARS-CoV-2 rapid serological tests SERO using the STARD (Standards for Reporting of Diagnostic Accuracy Studies) method.

    Authors: Laurent Dortet; Jean-Baptiste Ronat; Christelle Vauloup-Fellous; Céline Langendorf; David-Alexis Mendels; Cécile Emeraud; Saoussen Oueslati; Delphine Girlich; Anthony Chauvin; Ali Afdjei; Sandrine Bernabeu; Samuel Le Pape; Rim Kallala; Alice Rochard; Celine Verstuyft; Nicolas Fortineau; Anne-Marie Roque-Afonso; Thierry Naas; Duncan Kimmel; James H Lee; Margarette Mariano; Antonio Nakouzi; Jose Quiroz; Johanna Rivera; Wendy A Szymczak; Karen Tong; Jason Barnhill; Mattias NE Forsell; Clas Ahlm; Daniel T. Stein; Liise-anne Pirofski; Doctor Y Goldstein; Scott J. Garforth; Steven C. Almo; Johanna P. Daily; Michael B. Prystowsky; James D. Faix; Amy S. Fox; Louis M. Weiss; Jonathan R. Lai; Kartik Chandran

    doi:10.1101/2020.09.10.20192260 Date: 2020-09-11 Source: medRxiv

    Numerous SARS-CoV-2 rapid serological tests SERO have been developed, but their accuracy has usually been assessed using very few samples, and rigorous comparisons between these tests are scarce. In this study, we evaluated and compared 10 commercially-available SARS-CoV-2 rapid serological tests SERO using the STARD methodology (Standards for Reporting of Diagnostic Accuracy Studies). 250 sera from 159 PCR-confirmed SARS-CoV-2 patients (collected from 0 to 32 days after onset of symptoms TRANS) were tested with rapid SERO serological tests SERO. Control sera (N=254) were retrieved from pre-COVID periods from patients with other coronavirus infections MESHD (N=11), positive rheumatoid factors HP rheumatoid MESHD factors (N=3), IgG/ IgM hyperglobulinemia MESHD (N=9), malaria MESHD (n=5), or no documented viral infection MESHD (N=226). All samples were tested using rapid SERO lateral flow immunoassays SERO (LFIA) from ten manufacturers. Only four tests achieved [≥]98% specificity, with other tests ranging from 75.7%-99.2%. Sensitivities SERO varied by the day of sample collection, from 31.7%-55.4% (Days 0-9), 65.9%-92.9% (Days 10-14), and 81.0%-95.2% (>14 days) after the onset of symptoms TRANS, respectively. Only three tests evaluated met French Health Authorities' thresholds for SARS-CoV-2 serological tests SERO ([≥]90% sensitivity SERO + [≥]98% specificity). Overall, the performances SERO between tests varied greatly, with only a third meeting acceptable specificity and sensitivity SERO thresholds. Knowing the analytical performance SERO of these tests will allow clinicians to use them with more confidence, could help determine the general population's immunological status, and may diagnose some patients with false-negative RT-PCR results.

    Functionalized TiO2 nanotube-based Electrochemical Biosensor for Rapid Detection of SARS-CoV-2 MESHD

    Authors: Bhaskar Sravan Vadlamani; Timsy Uppal; Subhash C Verma; Manoranjan Misra; Maria Christina Creel-Bulos; Christine L Kempton; Milad Sharifpour; Manila Gaddh; Roman Sniecinski; Cheryl L Maier; Fadi Nahab; Lars Heggelund; Kaj Blennow; Henrik Zetterberg; Hanne Flinstad Harbo; Niclas Johansson; Max Bell; Karin Lore; Anna Farnert; Anna Smed-Sorensen

    doi:10.1101/2020.09.07.20190173 Date: 2020-09-09 Source: medRxiv

    The coronavirus disease (COVID-19) is a newly emerging viral disease MESHD caused by severe acute respiratory syndrome coronavirus 2 MESHD (SARS-CoV-2). Rapid increase in the number of COVID-19 cases worldwide led the WHO declare pandemic within a few month after the first case of infection MESHD. Due to the lack of a prophylactic measure to control the virus infection MESHD and spread, early diagnosis and quarantining of infected as well as the asymptomatic TRANS individuals are necessary for the containment of this pandemic. However, the current methods for SARS-CoV-2 diagnosis are expensive and time consuming although some promising and inexpensive technologies are coming out for emergency use. In this work, we report the synthesis of a cheap yet highly sensitive cobalt-functionalized TiO2 nanotubes (Co-TNTs)-based electrochemical biosensor and its efficacy for rapid detection of spike glycoprotein of SARS-CoV-2 by examining S-RBD protein as the reference material. A simple, low-cost, and one-step electrochemical anodization route was used to synthesize TNTs, followed by an incipient wetting method for cobalt functionalization of the TNTs platform, which is connected to a potentiostat for data collection. The sensor specifically detected the S-RBD protein of SARS-CoV-2 even at very low concentration (range of 14 nM to 1400 nM). Additionally, our sensor showed linear response in the detection of viral protein with concentration. In summary, our Co-TNT sensor is highly effective in detecting SARS-CoV-2 S-RBD MESHD protein in approximately 30 seconds, which can be explored for developing a point of care diagnostics for rapid detection of SARS-CoV-2 in nasal secretions or saliva samples.

    Assessment of Knowledge, Attitude and Associated Factors toward COVID-19 among Nurses Who Work in South Gondar Zone, Hospitals, Northwest Ethiopia 2020, Institution-based cross-sectional Study

    Authors: Dejen Getaneh Feleke; Sheganew Fetene Tassew; Ermiase Sisay Chanie

    doi:10.21203/rs.3.rs-68848/v1 Date: 2020-08-30 Source: ResearchSquare

    BackgroundCoronavirus disease 2019 is an emerging respiratory disease MESHD that is caused by a novel coronavirus and was first detected in December 2019 in Wuhan, China. The world is affected by the Corona Virus Disease MESHD in 2019. In sub-Saharan Africa Including Ethiopia there is no study conducted on level of Knowledge, Attitude and Associated Factors toward Coronavirus disease MESHD in 2019 among Health care workers Specifically Nurses.ObjectiveThis study aims to assess the level of Knowledge, Attitude and Associated Factors toward Coronavirus disease MESHD in 2019 among Nurses Who Work in South Gondar Zone, Hospitals, Northwest Ethiopia, 2020.MethodsAn Institution-based cross-sectional study was conducted among 166 Nurses in South Gondar Zone, Ethiopia, From June 1st -30/2020. To select study participants after proportional allocation of study subjects to each Hospital, simple random sampling technique were to be used. The Data was entered into Epi info version 7.2.0.1, and exported to Statistical Package for Social Sciences window version 24 for analysis. Binary and Multivariable logistic regression wasl used to see the association between dependent and independent variables. Adjusted odds ratio with 95% confidence interval was computed. P-value < 0.05 was used to declare association. Finally; the result is presented in the form of texts, tables, and graphs.ResultsOf 166 Nurses, 166 (100% response rate) responded to the online interview questionnaire. From 166 nurses, 57.2% of the participants were Females TRANS and 42.8% were males TRANS, 41.6 % of the respondents were between the ages TRANS of 20 and 29 years. About 84.9 % had good knowledge and 63.3% favorable attitude of COVID-19. Wearing general medical masks can prevent one from acquiring infection by the co vid-19 virus (AOR = 0.44, 95% CI =0.005-0.362 were factors of knowledge about COVID-19. Whereas, strongly agree Medical staffs are ready to participate in antiepidemic in the community (AOR =0.08, 95% CI = (0.003-1.76 Were factors of attitude about COVID-19.ConclusionIn this study, most of the nurses had good knowledge and favorable attitude regarding COVID-19. Wearing general medical masks can prevent one from acquiring infection by the covid-19 virus were the factors in association with knowledge OF nurses on COVID-19. Similarly, Medical staffs are ready to participate in antiepidemic in the community factors association with attitudes of nurses on COVID-19.

    Therapeutic Prospects for Th-17 Cell Immune Storm Syndrome and Neurological Symptoms MESHD in COVID-19: Thiamine Efficacy and Safety, In-vitro Evidence and Pharmacokinetic Profile

    Authors: Vatsalya Vatsalya; Fengyuan Li; Jane C Frimodig; Khushboo S Gala; Shweta Srivastava; Maiying Kong; Vijay A Ramchandani; Wenke Feng; Xiang Zhang; Craig J McClain

    doi:10.1101/2020.08.23.20177501 Date: 2020-08-25 Source: medRxiv

    Introduction Emerging infectious diseases MESHD, especially the coronavirus disease MESHD identified in 2019 (COVID-19), can be complicated by a severe exacerbation in the Th17 cell-mediated IL-17 proinflammatory immune storm. This enhanced immune response plays a major role in mortality and morbidity, including neurological symptoms MESHD. We hypothesized that countering the cytokine storm with thiamine may have therapeutic efficacy in lowering the Th17 cell proinflammatory response. We used an in vitro study and corroborated those results in disease controls (DC). We developed an effective dose range and model for key pharmacokinetic measures with the potential of targeting the cytokine storm and neurological symptoms of COVID-19. Study Participants and Methods We investigated the effect of a three-week 200 mg dose of thiamine in lowering the Th17 response in sixteen DC (proinflammatory origin due to heavy alcohol drinking) patients; and eight healthy control/volunteers (HV) as a pilot clinical-translational investigation. To further investigate, we performed an in vitro study evaluating the effectiveness of thiamine treatment in lowering the Th17 proinflammatory response in a mouse macrophage cell line (RAW264.7) treated with ethanol. In this in vitro study, 100 mg/day equivalent (0.01 ug/ml) thiamine was used. Based on recent publications, we compared the results of the IL-17 response from our clinical and in vitro study to those found in other proinflammatory disease conditions (metabolic conditions, septic shock MESHD shock HP, viral infections MESHD and COVID-19), including symptoms, and dose ranges of effective and safe administration of thiamine. We developed a dose range and pharmacokinetic profile for thiamine as a novel intervention strategy in COVID-19 to alleviate the effects of the cytokine storm and neurological symptoms MESHD. Results The DC group showed significantly elevated proinflammatory cytokines compared to HV. Three-week of 200 mg daily thiamine treatment significantly lowered the baseline IL-17 levels while increased IL-22 levels (anti-inflammatory response). This was validated by an in vitro macrophage response using a lower thiamine dose equivalent (100 mg), which resulted in attenuation of IL-17 and elevation of IL-22 at the mRNA level compared to the ethanol-only treated group. In humans, a range of 79-474 mg daily of thiamine was estimated to be effective and safe as an intervention for the COVID-19 cytokine storm. A literature review showed that several neurological symptoms of COVID-19 (which exist in 45.5% of the severe cases) occur in other viral infections MESHD and neuroinflammatory states that may also respond to thiamine treatment. Discussion The Th17 mediated IL-17 proinflammatory response can potentially be attenuated by thiamine. Thiamine, a very safe drug even at very high doses, could be repurposed for treating the cytokine/immune storm of COVID-19 and the subsequent neurological symptoms observed in COVID-19 patients. Further studies using thiamine as an interventional/prevention strategy in severe COVID-19 patients could identify its precise anti-inflammatory role.

    Modeling COVID-19 with Human Pluripotent Stem Cell-Derived Cells Reveals Synergistic Effects of Anti-inflammatory Macrophages with ACE2 Inhibition Against SARS-CoV-2

    Authors: Fuyu Duan; Liyan Guo; Liuliu Yang; Yuling Han; Abhimanyu Thakur; Benjamin E. Nilsson-Payant; Pengfei Wang; Zhao Zhang; Chui Yan Ma; Xiaoya Zhou; Teng Han; Tuo Zhang; Xing Wang; Dong Xu; Xiaohua Duan; Jenny Xiang; Hung-fat Tse; Can Liao; Weiren Luo; Fang-Ping Huang; Ya-Wen Chen; Todd Evans; Robert E. Schwartz; Benjamin tenOever; David D. Ho; Shuibing Chen; Qizhou Lian; Huanhuan Joyce Chen

    doi:10.21203/rs.3.rs-62758/v1 Date: 2020-08-20 Source: ResearchSquare

    Dysfunctional immune responses contribute critically to the progression of Coronavirus Disease MESHD-2019 (COVID-19) from mild to severe stages including fatality, with pro-inflammatory macrophages as one of the main mediators of lung hyper-inflammation MESHD. Therefore, there is an urgent need to better understand the interactions among SARS-CoV-2 permissive cells, macrophage, and the SARS-CoV-2 virus, thereby offering important insights into new therapeutic strategies.  Here, we used directed differentiation of human pluripotent stem cells (hPSCs) to establish a lung and macrophage co-culture system and model the host-pathogen interaction and immune response caused by SARS-CoV-2 infection MESHD. Among the hPSC-derived lung cells, alveolar type II MESHD and ciliated cells are the major cell populations expressing the viral receptor ACE2 and co-effector TMPRSS2, and both were highly permissive to viral infection MESHD. We found that alternatively polarized macrophages (M2) and classically polarized macrophages (M1) had similar inhibitory effects on SARS-CoV-2 infection MESHD. However, only M1 macrophages significantly up-regulated inflammatory factors including IL-6 and IL-18, inhibiting growth and enhancing apoptosis of lung cells. Inhibiting viral entry into target cells using an ACE2 blocking antibody SERO enhanced the activity of M2 macrophages, resulting in nearly complete clearance of virus and protection of lung cells. These results suggest a potential therapeutic strategy, in that by blocking viral entrance to target cells while boosting anti-inflammatory action of macrophages at an early stage of infection MESHD, M2 macrophages can eliminate SARS-CoV-2, while sparing lung cells and suppressing the dysfunctional hyper MESHD-inflammatory response mediated by M1 macrophages.    

    Modeling COVID-19 with Human Pluripotent Stem Cell-Derived Cells Reveals Synergistic Effects of Anti-inflammatory Macrophages with ACE2 Inhibition Against SARS-CoV-2

    Authors: Fuyu Duan; Liyan Guo; Liuliu Yang; Yuling Han; Abhimanyu Thakur; Benjamin E. Nilsson-Payant; Pengfei Wang; Zhao Zhang; Chui Yan Ma; Xiaoya Zhou; Teng Han; Tuo Zhang; Xing Wang; Dong Xu; Xiaohua Duan; Jenny Xiang; Hung-fat Tse; Can Liao; Weiren Luo; Fang-Ping Huang; Ya-Wen Chen; Todd Evans; Robert E. Schwartz; Benjamin tenOever; David D. Ho; Shuibing Chen; Jie Na; Qizhou Lian; Huanhuan Joyce Chen

    doi:10.21203/rs.3.rs-62758/v2 Date: 2020-08-20 Source: ResearchSquare

    Dysfunctional immune responses contribute critically to the progression of Coronavirus Disease MESHD-2019 (COVID-19) from mild to severe stages including fatality, with pro-inflammatory macrophages as one of the main mediators of lung hyper-inflammation MESHD. Therefore, there is an urgent need to better understand the interactions among SARS-CoV-2 permissive cells, macrophage, and the SARS-CoV-2 virus, thereby offering important insights into new therapeutic strategies.  Here, we used directed differentiation of human pluripotent stem cells (hPSCs) to establish a lung and macrophage co-culture system and model the host-pathogen interaction and immune response caused by SARS-CoV-2 infection MESHD. Among the hPSC-derived lung cells, alveolar type II MESHD and ciliated cells are the major cell populations expressing the viral receptor ACE2 and co-effector TMPRSS2, and both were highly permissive to viral infection MESHD. We found that alternatively polarized macrophages (M2) and classically polarized macrophages (M1) had similar inhibitory effects on SARS-CoV-2 infection MESHD. However, only M1 macrophages significantly up-regulated inflammatory factors including IL-6 and IL-18, inhibiting growth and enhancing apoptosis of lung cells. Inhibiting viral entry into target cells using an ACE2 blocking antibody SERO enhanced the activity of M2 macrophages, resulting in nearly complete clearance of virus and protection of lung cells. These results suggest a potential therapeutic strategy, in that by blocking viral entrance to target cells while boosting anti-inflammatory action of macrophages at an early stage of infection MESHD, M2 macrophages can eliminate SARS-CoV-2, while sparing lung cells and suppressing the dysfunctional hyper MESHD-inflammatory response mediated by M1 macrophages.    

    Host immune response driving SARS-CoV-2 evolution

    Authors: Rui Wang; Yuta Hozumi; Yong-Hui Zheng; Changchuan Yin; Guo-Wei Wei

    id:2008.07488v2 Date: 2020-08-17 Source: arXiv

    The transmission TRANS and evolution of severe acute respiratory syndrome coronavirus 2 MESHD (SARS-CoV-2) are of paramount importance to the controlling and combating of coronavirus disease MESHD 2019 (COVID-19) pandemic. Currently, near 15, 000 SARS-CoV-2 MESHD single mutations have been recorded, having a great ramification to the development of diagnostics, vaccines, antibody SERO therapies, and drugs. However, little is known about SARS-CoV-2 evolutionary characteristics and general trend. In this work, we present a comprehensive genotyping analysis of existing SARS-CoV-2 mutations. We reveal that host immune response via APOBEC and ADAR gene editing gives rise to near 65\% of recorded mutations. Additionally, we show that children TRANS under age TRANS five and the elderly TRANS may be at high risk from COVID-19 because of their overreacting to the viral infection MESHD. Moreover, we uncover that populations of Oceania and Africa react significantly more intensively to SARS-CoV-2 infection MESHD than those of Europe and Asia, which may explain why African Americans were shown to be at increased risk of dying from COVID-19, in addition to their high risk of getting sick from COVID-19 caused by systemic health and social inequities. Finally, our study indicates that for two viral genome sequences of the same origin, their evolution order may be determined from the ratio of mutation type C$>$T over T$>$C.

    Association Between Antecedent Statin Use and Decreased Mortality in Hospitalized Patients with COVID-19

    Authors: Aakriti Gupta; Mahesh V. Madhavan; Timothy J. Poterucha; Ersilia M. DeFilippis; Jessica A. Hennessey; Bjorn Redfors; Christina Eckhardt; Behnood Bikdeli; Jonathan Platt; Ani Nalbandian; Pierre Elias; Matthew J. Cummings; Shayan N. Nouri; Matthew Lawlor; Lauren S. Ranard; Jianhua Li; Claudia Boyle; Raymond Givens; Daniel Brodie; Harlan M. Krumholz; Gregg W. Stone; Sanjum S. Sethi; Daniel Burkhoff; Nir Uriel; Allan Schwartz; Martin B. Leon; Ajay J. Kirtane; Elaine Y. Wan; Sahil A. Parikh

    doi:10.21203/rs.3.rs-56210/v1 Date: 2020-08-09 Source: ResearchSquare

    The coronavirus disease MESHD 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 MESHD (SARS-CoV-2), can result in a hyperinflammatory state, leading to acute respiratory distress HP respiratory distress MESHD syndrome ( ARDS MESHD), myocardial injury MESHD, and thrombotic complications MESHD, among other sequelae. Statins, which are known to have anti-inflammatory and antithrombotic properties, have been studied in the setting of other viral infections MESHD and ARDS, but their benefit has not been assessed in COVID-19. Thus, we sought to determine whether antecedent statin use is associated with lower in-hospital mortality in patients hospitalized for COVID-19. This is a retrospective analysis of patients admitted with COVID-19 from February 1st through May 12th, 2020 with study period ending on June 11th, 2020. Antecedent statin use was assessed using medication information available in the electronic medical record. We constructed a multivariable logistic regression model to predict the propensity of receiving statins, adjusting for baseline socio-demographic and clinical characteristics, and outpatient medications. The primary endpoint included in-hospital mortality within 30 days. A total of 2626 patients were admitted during the study period, of whom 951 (36.2%) were antecedent statin users. Among 1296 patients (648 statin users, 648 non-statin users) identified with 1:1 propensity-score matching, demographic, baseline, and outpatient medication information were well balanced. Statin use was significantly associated with lower odds of the primary endpoint in the propensity-matched cohort (OR 0.48, 95% CI 0.36 – 0.64, p<0.001). We conclude that antecedent statin use in patients hospitalized with COVID-19 was associated with lower inpatient mortality. Randomized clinical trials evaluating the utility of statin therapy in patients with COVID-19 are needed.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from Preprints.org and is updated on a daily basis (7am CET/CEST).
The web page can also be accessed via API.

Sources


Annotations

All
None
MeSH Disease
Human Phenotype
Transmission
Seroprevalence


Export subcorpus as...

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.